Search Names & Symbols
DISCLAIMER:
Friday, December 30, 2022
Wednesday, December 21, 2022
Tuesday, December 20, 2022
Sunday, December 11, 2022
Thursday, November 10, 2022
Tuesday, September 27, 2022
Saturday, September 24, 2022
Tuesday, September 20, 2022
Monday, September 19, 2022
Wednesday, September 14, 2022
Tuesday, September 13, 2022
Monday, September 12, 2022
Sunday, September 11, 2022
Wednesday, August 31, 2022
Monday, August 29, 2022
Bayer initiates landmark Phase III study program to investigate oral FXIa inhibitor asundexian
|
---|
Saturday, August 27, 2022
Friday, August 26, 2022
Thursday, August 25, 2022
Monday, August 15, 2022
Sunday, August 14, 2022
Saturday, August 13, 2022
Friday, August 12, 2022
Thursday, August 11, 2022
Wednesday, August 10, 2022
Tuesday, August 9, 2022
Volta Media™ Network Surpasses One Billion Monthly Impressions and More Than 30,000 Tons of CO2 Emissions Avoided
Volta attracts larger digital media budgets with expanded measurement, programmatic buying, and data-driven targeting capabilities for advertisers
SAN FRANCISCO--(BUSINESS WIRE)-- Volta
Tuesday, July 26, 2022
Monday, July 25, 2022
Sunday, July 24, 2022
Thursday, July 21, 2022
Vir Biotechnology to Provide Corporate Update and Report Second Quarter 2022 Financial Results on August 4, 2022
sAN FRANCISCO, July 21, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced the Company will provide a corporate update and report financial results for the second quarter ended June 30, 2022, on Thursday, August 4, 2022.
The corporate update and financial results will be provided via a press release after market close and will be accessible under Press Releases in the Investors section of the Vir website at www.vir.bio.
About Vir Biotechnology
Vir Biotechnology is a commercial-stage immunology company focused on combining immunologic insights with cutting-edge technologies to treat and prevent serious infectious diseases. Vir has assembled four technology platforms that are designed to stimulate and enhance the immune system by exploiting critical observations of natural immune processes. Its current development pipeline consists of product candidates targeting COVID-19, hepatitis B and D viruses, influenza A and human immunodeficiency virus. Vir routinely posts information that may be important to investors on its website.
Contacts: Investors Heather Rowe Armstrong VP, Investor Relations harmstrong@vir.bio +1-415-915-4228 Media Carly Scaduto Senior Director, Media Relations cscaduto@vir.bio +1 314-368-5189
Wednesday, July 20, 2022
Tuesday, July 19, 2022
Monday, July 18, 2022
Sunday, July 17, 2022
Saturday, July 16, 2022
Vroom Announces Pricing of UACC Auto Loan Securitization
Vroom Announces Pricing of UACC Auto Loan Securitization
The Q3 2022 securitization is a private offering under Rule 144A in which UACC offered approximately
UACC expects to sell approximately
Friday, July 15, 2022
Thursday, July 14, 2022
Bayer to sell men’s health product Nebido™ to Grünenthal
Bayer to sell men’s health product Nebido™ to Grünenthal
|
---|
|
---|
Tuesday, July 12, 2022
Monday, July 11, 2022
Sunday, July 10, 2022
Thursday, July 7, 2022
Wednesday, July 6, 2022
Tuesday, July 5, 2022
Monday, July 4, 2022
Sunday, July 3, 2022
Saturday, July 2, 2022
Friday, July 1, 2022
CLOU - ETF FOR THE FUTURE
CLOU - ETF FOR THE FUTURE by StockBlog on TradingView.com
After the big drop in tech stocks in recent months, this etf , that follows cloud companies, is a very good investment option for those who look to the future...
Thursday, June 30, 2022
Monday, June 27, 2022
Sunday, June 26, 2022
Vir Biotechnology Announces New Clinical Data From its Broad Hepatitis B Program
– Results from ongoing trials of VIR-2218 and VIR-3434 presented at the International
Liver Congress™ (ILC) 2022 demonstrate durable reductions in hepatitis B surface antigen with no safety signals –
– Company expects to dose first patient in Part B of the Phase 2 MARCH trial by the end of June –
SAN FRANCISCO, June 25, 2022 (GLOBE NEWSWIRE) -- Vir Biotechnology, Inc. (Nasdaq: VIR) today announced new data from its robust hepatitis B virus (HBV) clinical trial program, including results from an ongoing Phase 2 clinical trial of VIR-2218, results from an ongoing Phase 1 clinical trial of VIR-3434 and preclinical data evaluating both investigational compounds as monotherapy and in combination. Data were presented in one oral and two poster presentations at the International Liver Congress™ (ILC) 2022, the Annual Meeting of the European Association for the Study of the Liver (EASL).
Friday, June 24, 2022
Thursday, June 23, 2022
Wednesday, June 22, 2022
Tuesday, June 21, 2022
Monday, June 20, 2022
Sunday, June 19, 2022
Saturday, June 18, 2022
WINNER OF THE WEEK
Unipro (UPRO)
The best online stock broker. Open an account today and start earning up to $1000 of IBKR Stock !
DISCLAIMER: The financial and technical analycies presented on this website have not
been performed by an Investment Services Company, nor have they been compiled
by a certified analyst . It is simply a display and presentation of public data
of Greek and foreign shares with informative and entertaining character.